12:00 AM
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bydureon exenatide once weekly regulatory update

The Scottish Medicines Consortium recommended the restricted use of once-weekly Bydureon exenatide on the National Health Service (NHS) in Scotland only as a third-line treatment option for Type II diabetes. According...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >